<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991506</url>
  </required_header>
  <id_info>
    <org_study_id>ES102-1002</org_study_id>
    <nct_id>NCT04991506</nct_id>
  </id_info>
  <brief_title>A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES102 in Combination With JS001 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elpiscience Biopharma, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Elpiscience Biopharma, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT),&#xD;
      Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 agonist)&#xD;
      in combination with JS001 (anti-PD-1 checkpoint inhibitor) in patients with advanced solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>2-4 years</time_frame>
    <description>Maximum Tolerated Dose (MTD) of ES102 in combination with JS001</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of adverse events of ES102 in combination with JS001</measure>
    <time_frame>2-4 years</time_frame>
    <description>The safety profile of ES102 in combination with JS001 will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D</measure>
    <time_frame>2-4 years</time_frame>
    <description>Recommended Phase 2 Dose (RP2D) of ES102 in combination with JS001</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration time curve (AUC) of ES102 in combination with JS001</measure>
    <time_frame>2-4 years</time_frame>
    <description>Area under the serum concentration time curve (AUC) of ES102 in combination with JS001 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration of ES102 in combination with JS001</measure>
    <time_frame>2-4 years</time_frame>
    <description>Maximum observed serum concentration of ES102 in combination with JS001 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough) of ES102 in combination with JS001</measure>
    <time_frame>2-4 years</time_frame>
    <description>Trough observed serum concentration (Ctrough) of ES102 in combination with JS001 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of ES102 in combination with JS001</measure>
    <time_frame>2-4 years</time_frame>
    <description>Time to Cmax (Tmax) of ES102 in combination with JS001 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of ES102 in combination with JS001</measure>
    <time_frame>2-4 years</time_frame>
    <description>Frequency of anti-drug antibodies (ADA) against ES102 in combination with JS001 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of ES102 in combination with JS001</measure>
    <time_frame>2-4 years</time_frame>
    <description>Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Neoplasms</condition>
  <condition>Malignant Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1 ES102 Escalation in combination with JS001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ES102 will be escalated, in combination with JS001, in patients with advanced solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 ES102 Expansion in combination with JS001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with advanced non-small cell lung cancer, advanced esophageal squamous cell carcinoma, nasopharyngeal carcinoma and other advanced solid tumors will be treated with ES102 at the RP2D in combination with JS001.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ES102</intervention_name>
    <description>The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)</description>
    <arm_group_label>Part 1 ES102 Escalation in combination with JS001</arm_group_label>
    <arm_group_label>Part 2 ES102 Expansion in combination with JS001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS001</intervention_name>
    <description>JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.</description>
    <arm_group_label>Part 1 ES102 Escalation in combination with JS001</arm_group_label>
    <arm_group_label>Part 2 ES102 Expansion in combination with JS001</arm_group_label>
    <other_name>Toripalimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Males or females aged ≥18 years.&#xD;
&#xD;
          -  2.Ability to understand and the willingness to sign a written informed consent form.&#xD;
&#xD;
          -  3.Subjects with pathological or cytological diagnosed advanced solid tumor, whose&#xD;
             disease has progressed despite standard therapies, or for whom no further standard&#xD;
             therapy exists, or who is unsuitable for available standard therapies and at least has&#xD;
             progressed after receiving first line therapy.In Part 2 (dose expansion) also includes&#xD;
             the following contents: D1 &amp; D2:Subjects with advanced NSCLC, has progressed or&#xD;
             relapsed after receiving at least one platinum-containing regimen and any of&#xD;
             anti-PD-1/PD-L1 therapy; D3: Subjects with advanced ESCC, has progressed or relapsed&#xD;
             with or without any of anti-PD-1/PD-L1 therapy; D4: Subjects with advanced NPC, has&#xD;
             progressed or relapsed after receiving any of anti-PD-1/PD-L1 therapy; D5: Subjects&#xD;
             with other advanced solid tumors including GI, Cervical cancer, triple-negative BC or&#xD;
             SCLC.&#xD;
&#xD;
          -  4.All subjects with NSCLC have documentation of absence of tumor activating EGFR&#xD;
             mutation and absence of ALK and ROS1 gene rearrangements.&#xD;
&#xD;
          -  5.PD-L1 by IHC: Parts 1 and Part 2 D3-D5: IHC result mandatory but any score allowed.&#xD;
             Part 2 D1-D2: Tumor Proportion Score (TPS) ≥ 1%.&#xD;
&#xD;
          -  6.At least one measurable lesion is required (RECIST v1.1)&#xD;
&#xD;
          -  7.Adequate hematologic, coagulation, hepatic and renal function as defined per&#xD;
             protocol.&#xD;
&#xD;
          -  8.Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.&#xD;
&#xD;
          -  9.Estimated life expectancy, in the judgment of the investigator, of at least 12&#xD;
             weeks.&#xD;
&#xD;
          -  10.Male and female subjects of childbearing potential and their spouses must be&#xD;
             willing to use feasible contraceptive methods considered effective by the&#xD;
             investigator, from the time of signing informed consent and for the duration of study&#xD;
             participation through 3 months, following the last dose of study drug. Postmenopausal&#xD;
             women are considered to have no fertility potential only if menostasis lasts for at&#xD;
             least 12 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Prior exposure to OX40 agonists.&#xD;
&#xD;
          -  2.Receipt of any anticancer investigational product or any approved anticancer drug(s)&#xD;
             or biological product(s) within 4 weeks prior to the first dose of study drug with&#xD;
             certain exceptions.&#xD;
&#xD;
          -  3.Receipt of non-CNS adjuvant radiation therapy within 1 week prior to the first dose,&#xD;
             receipt of radiation therapy within 2 weeks or with radiation pneumonia, have not&#xD;
             recovered from radiation-related toxicity or still require hormonal treatment for&#xD;
             radiation-related toxicity.&#xD;
&#xD;
          -  4.Known allergies to CHO-produced antibodies, which in the opinion of the Investigator&#xD;
             suggests an increased potential for an adverse hypersensitivity to ES102.&#xD;
&#xD;
          -  5.Subjects with allergic reactions to the active ingredients of JS001 or any of the&#xD;
             excipients.&#xD;
&#xD;
          -  6.Treatment with systemic immunosuppressive medications within 4 weeks prior to the&#xD;
             first dose of study drug. Certain exceptions as defined in protocol apply.&#xD;
&#xD;
          -  7.Receipt of live viral vaccine treatment within 4 weeks prior to the first dose of&#xD;
             the study drug.&#xD;
&#xD;
          -  8.Prior organ allograft transplantations or allogeneic peripheral blood stem cell&#xD;
             (PBSC) or bone marrow (BM) transplantation.&#xD;
&#xD;
          -  9.Subjects with primary or metastatic brain or meningeal tumors. Exceptions as defined&#xD;
             in protocol for Part 2 will apply.&#xD;
&#xD;
          -  10.Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to&#xD;
             discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.&#xD;
&#xD;
          -  11.Subject has not recovered from all AEs of previous anticancer therapies to baseline&#xD;
             or ≤ Grade 1 per CTCAE v5.0 before the first dose of study drug. Certain exceptions as&#xD;
             defined in protocol apply.&#xD;
&#xD;
          -  12.Hematologic malignancies.&#xD;
&#xD;
          -  13.Receipt of treatment with G-CSF, GM-CSF, Thrombopoietic drugs or EPO within 14 days&#xD;
             prior to the first dose of the study drug.&#xD;
&#xD;
          -  14.Patients with other malignancies within 2 years before screening shall be excluded&#xD;
             in Part B. Some exceptions as defined per protocol apply.&#xD;
&#xD;
          -  15.Active autoimmune disease or documented history of autoimmune disease that required&#xD;
             systemic steroids or other immunosuppressive medications. Certain exceptions as&#xD;
             defined in protocol apply.&#xD;
&#xD;
          -  16.Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or&#xD;
             pneumonitis requiring treatment with steroids or other immunosuppressive medications.&#xD;
&#xD;
          -  17.Clinically significant cardiac condition, including myocardial infarction,&#xD;
             uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart&#xD;
             disease &lt; 6 months; left ventricular ejection fraction (LVEF) &lt; 50%; New York Heart&#xD;
             Association (NYHA) Class III or IV congestive heart failure; or uncontrolled&#xD;
             hypertension.&#xD;
&#xD;
          -  18.History of pulmonary embolism within 12 weeks prior to the first dose of study drug&#xD;
             administration.&#xD;
&#xD;
          -  19.Major surgery within 4 weeks prior to enrollment on this trial.&#xD;
&#xD;
          -  20.History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)&#xD;
             infection for Part 1. Exceptions as defined in protocol for Part 2 will apply.&#xD;
&#xD;
          -  21.Receiving the systemic anti-infectious drug treatments within 4 weeks prior to the&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  22.Pregnant or nursing females.&#xD;
&#xD;
          -  23.Any known, documented, or suspected history of substance abuse that would preclude&#xD;
             subject from participation, certain exceptions as defined in protocol apply.&#xD;
&#xD;
          -  24.The subject is inappropriate to participate in this study for other reasons in the&#xD;
             judgment of the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ning Chen</last_name>
    <phone>86 15021415086</phone>
    <email>clinical-operation@elpiscience.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Zhang</last_name>
      <phone>86 0431-80596067</phone>
      <email>JPCHIRB@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ES102</keyword>
  <keyword>JS001</keyword>
  <keyword>OX40</keyword>
  <keyword>PD-1</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Phase 1</keyword>
  <keyword>INBRX-106</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

